Introduction {#s0005}
============

Ureteric stents were first described by Zimskind et al. in 1967 [@b0005]. The JJ ureteric stent has become an integral part of urological treatment options. The original indication for placing a ureteric stent was to treat a ureteric obstruction or fistula, but the current indications have expanded significantly ([Table 1](#t0005){ref-type="table"}) [@b0010]. The characteristics of the ideal ureteric stent [@b0015] include: easily inserted from any access; resistant to migration; optimal flow characteristics; well tolerated by the patient; biocompatible; bio-durable; resistant to encrustation; non-refluxing; radio-opaque or visible with ultrasonography; easily exchanged and removed; versatile; and affordable. However, different complications can occur with the short- or long-term use of indwelling stents [@b0020; @b0025]. These complications have varied from minor side-effects such as haematuria, dysuria, frequency, flank and suprapubic pain, to major complications such as vesico-ureteric reflux, migration, malposition, encrustation, stent fracture, UTI, pyuria, incontinence, inadequate relief of obstruction, ureteric erosion or fistulation, a 'forgotten stent', necrosis and uretero-arterial fistula. Most complications require removal of the indwelling catheter.

A serious limitation of previous studies that assessed the complications of JJ stenting was the inclusion of too few patients. In the present study we retrospectively reviewed our experience with JJ stenting to determine factors affecting the development of complications and the outcome of stenting.

Patients and methods {#s0010}
====================

Between April 2005 and May 2009, 220 patients (133 males and 87 females; mean age 39.5 years, SD 15.4, range 4--86) had self-retaining ureteric JJ stents placed at our centre, and were retrospectively included in the study with the approval of the hospital ethics committee.

Procedure {#s0015}
---------

The JJ stent was placed with the patient under general anaesthesia and in the lithotomy position, the size and length of the stent being selected by the surgeon, depending on the patient's body size and the calibre of the ureter. Using a 22 F cystoscope the stent was placed in position over a guidewire under fluoroscopy monitoring and its position confirmed. A plain film of the abdomen was taken as needed, to confirm the position of the stent. Patients were followed up in the clinic at 2--4 weeks and depending on the indication for stent placement, the stent was removed by flexible cystoscopy under local anaesthesia.

Statistical analysis {#s0020}
--------------------

Univariate (chi-square or *t*-test) and multivariate (logistic regression) analyses were used to identify significant variables affecting the development of complications and the outcomes of stenting. The latter can be interpreted in terms of success and complication rates. Success was defined as achieving the indication for stent insertion (e.g. less pain, less obstruction) and if the stent was well positioned, as confirmed by fluoroscopy or an abdominal plain film. The tested variables were patients' age, sex, indication for stenting, side of the stent, pre-stenting urine culture, the use of prophylactic antibiotics at the time of stent insertion, and the development of UTI. Stent characteristics were also tested, i.e. the material, length, diameter and duration of stenting. The site of the upper coil (whether in the renal pelvis or calyx), as well as the site of the lower coil (whether on the same side or crossing the midline) and the shape of the lower coil (whether a complete circle or not), were also assessed. The stents used were made of soft polyurethane (Cook double pigtail stent set, Cook Ireland Ltd., Eire) in all the patients so this was not included in the analysis.

Results {#s0025}
=======

In the present study, the most common indication for inserting a self-retaining JJ ureteric stent was after ureteroscopy (44%). Stenting of the left ureter (52.7%) was slightly more common than of the right ureter (47.3%). The most common stent length and size used were 26 cm (48%) and 4.7 F (56%), respectively. The median (range) duration of stenting was 41.5 (4--990) days. The rate of changing the stent once was 4% and changing it twice was 0.5%. The most frequent position of the upper coil was in the renal pelvis (82.7%). The shape of the lower coil assumed a complete circle in 93% of the patients and crossed the midline in 33.6%. Prophylactic antibiotics, as one dose of ceftriaxone or gentamicin before the procedure, were given in 82% of patients. The documented rate of UTI before stenting was 12% and afterwards was 11.8% ([Table 2](#t0010){ref-type="table"}).

In the present study, 131 of the 220 patients (59.5%) developed complications due to the JJ stent. According to the modified Clavien classification [@b0030], there were grades I, II, IIIa, IIIb complications in 67 (30.4%), 39 (17.7%), two (0.9%) and 23 (10.5%) patients, respectively, and none of IVa, IVb and V. Loin pain (10.9%) and UTI (10.9%) were the most common complications, followed by dysuria (7.7%). Significant complications requiring treatment occurred in 29.1% of patients. In young patients (aged ⩽20 years) three of 11 had a 'forgotten' stent, while in patients aged 21--49 years loin pain was the most common complication, at 78% (32/41). However, in patients aged ⩾50 years UTI was more prominent, at 37.5% (nine of 24). The most common complication in males was loin pain (71%, 17/24) while in females UTI was the most common complication (63%, 14/24). Loin pain increased with an increase in stent diameter (*P* = 0.047). A positive urine culture after stenting was significantly associated with UTI and a forgotten stent (*P* \< 0.001). A stent duration of \<90 days was significantly associated with a lower complication rate in males (*P* = 0.046) and females (*P* = 0.01). In middle-aged patients the lower coil shape of an incomplete circle was associated with migration of the stent (*P* = 0.045). There were complications requiring hospital admission in 13 of the 220 patients (5.9%; four for ESWL, seven for ureteroscopy and two for percutaneous surgery). Acute pyelonephritis was managed with intravenous antibiotics, according to the urine culture results, and with antipyretics, without exchanging the stent. There was encrustation around the stent in five patients (2.3%) with a mean (range) stenting duration of 71.4 (30--131) days, and the encrustations were broken up at the time of stent removal.

The outcomes of ureteric stenting were 'improved' in 71.4% of patients (157/220), not improved in 16% (35/220), with 8.6% who died from their disease or from other comorbidities (19/220), and in 4% of patients the outcome was unknown (nine of 220).

On univariate analysis the significant factors affecting the complication rate were gender (*P* \< 0.001), stenting duration (*P* = 0.035), stent length (*P* = 0.046), and a positive urine culture after stenting (*P* \< 0.001; [Table 2](#t0010){ref-type="table"}), while significant factors affecting the outcome after stenting (improved or not) were patient age (*P* = 0.002), gender (*P* = 0.009), stenting duration (*P* = 0.002), stent length (*P* = 0.02), stent diameter (*P* = 0.002), and a positive urine culture before (*P* = 0.016) and after (*P* = 0.013) stenting ([Table 2](#t0010){ref-type="table"}).

On multivariate analysis the only significant independent factor affecting the complication rate was the stent length (*P* = 0.016), with a relative risk (95% CI) of 1.5 (1.1--2.1) ([Table 3](#t0015){ref-type="table"}). However, the only significant independent factor affecting the (improved) outcome was age (*P* = 0.014), with a relative risk of decreasing the outcome by 0.86 (0.765--0.971) for each year ([Table 3](#t0015){ref-type="table"}).

Discussion {#s0030}
==========

The softness of silicone material continues to be the standard against which modern stents are judged, but due to the high coefficient of friction of silicone, placing silicone stents is often difficult. This led to the use of polyethylene in the construction of stents, to provide stiffness as an aid for insertion. This material proved to be unstable in the urinary environment, which made polyethylene stents prone to early fracture. Polyurethane was then substituted, and it continues to be used in stent construction, either alone or combined with other materials. More recently, copolymers such as C-Flex (Concept Polymer Technologies, Clearwater, FL, USA), Percuflex (Boston Scientific, Natick, MA, USA), and Flexima (Boston Scientific) have been used in the construction of JJ or double-pigtail catheters. Hydrophilic gel coatings have been added to assist in placement, and to potentially reduce the prevalence of encrustation and complicating infection. Stents made of biodegradable materials and metal are also under investigation [@b0035]. The ureteric thermo-expandable metal segmental stent (Memokath, Engineers & Doctors A/S, Hornbaek, Denmark) is a promising, safe and efficient treatment option for the minimally invasive management of both benign and malignant ureteric strictures. Compared to conventional JJ stents there were improvements in general health and other quality-of-life variables, and there was a tendency in favour of the Memokath [@b0040; @b0045; @b0050].

Indwelling times can range from a few days for the relief of ureteric oedema to the duration of the patient's life when maintaining ureteric patency to avoid obstruction from malignant disease [@b0055]. Regardless of the stent composition, manufacturers usually recommend exchanging the stents at 3--6-month intervals, and studies have shown that the prevalence of complications increases with longer indwelling times [@b0060]. In the present study a stent duration of \<90 days was significantly associated with reduced complication rates in both males (*P* = 0.046) and females (*P* = 0.01). In the present study there were 20 patients who had stents left in place for \>180 days, due to forgotten stents (11), and encrustation or loss to follow-up (nine patients).

EL-Nahas et al. [@b0065], in a study of 100 patients to determine the significant factors affecting patients' discomfort during the period of temporary ureteric stenting, found that a positive urine culture, crossing of the lower end of the stent to the opposite side, calyceal position of the upper coil, and longer stenting duration were significant factors. On multivariate analysis in the present study, with more patients (220), the significant independent factor affecting the complication rate was stent length (*P* = 0.016), while the significant independent factor affecting the improved outcome was patient age (*P* = 0.014). The significant effect of stent length on the complication rate can be explained by the extra length of the intravesical part of the stent causing trigonal irritation, whereas the effect of age on the outcome can be attributed to increased comorbidities and less tolerance in the elderly population. The causes are not completely understood, but a high pressure transmitted to the renal pelvis with urination, and trigonal irritation by the intravesical part of the stent, are regarded as influencing factors [@b0070]. The shape of the lower coil (either a complete circle or not) and its position (either crossing the midline or not) are considered as other factors leading to discomfort [@b0075]. It was reported that larger-diameter stents are associated with more discomfort [@b0080]. In the present univariate analysis the stent diameter had a negative effect on the outcome (*P* = 0.002, regression coefficient -- 0.756). Also on univariate analysis, the stent diameter had no effect on the complication rate (*P* = 0.514). Thus larger stents were not associated with better outcomes or an increased complication rate. However, on univariate analysis, stent length had a positive effect on the complication rate (*P* = 0.046, regression coefficient 0.230) and a negative effect on the outcome (*P* = 0.02, regression coefficient -- 0.468). Thus longer stents were associated with an increased complication rate. Nevertheless, on multivariate analysis, stent length had a significant positive effect only on the complication rate (*P* = 0.016, regression coefficient 0.413). This could be explained by longer stents causing more irritation to the urinary urothelium. Interestingly, our data showed that increasing age is associated with a poor outcome after stenting (*P* = 0.014, regression coefficient -- 0.149). Akay et al. [@b0085] investigated the potential risk factors for lower UTI and bacterial stent colonisation in patients with JJ stents. They found that *Escherichia coli* was the most common pathogen, and diabetes mellitus, chronic renal failure, and pregnancy were associated with a higher risk of lower UTI in patients with stents. In the present study, the significant factors affecting the complication rate were patient gender, UTI after stenting, stenting duration and stent length, while significant factors affecting the outcome after stenting (improved or not) were patient age, sex, stenting duration, stent length, stent diameter, and a positive urine culture before and after stenting. However when confounding factors are considered, the only significant factor affecting the complication rate was the stent length and the only significant factor affecting the improved outcome was age.

In the present study 59.5% (131/220) of patients developed complications due to ureteric stenting, but there were significant complications requiring treatment in only 29.1% of patients. Loin pain (10.9%) and UTI (10.9%) were the most common complications, followed by dysuria (7.7%). Variable degrees of stent-related discomfort and morbidity are nevertheless reported by up to 80% of patients [@b0075].

In conclusion, a larger stent was not associated with increased complication rates or better outcomes. However, longer stents were associated with increased complication rates and the older the patient the more likely they were to have a poor outcome after stenting. Future prospective multicentre studies with more patients are needed to confirm the present conclusions.
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###### 

Indications for placing a JJ ureteric stent.

  Indications
  --------------------------------------------------------------------------------------------------------------------
  *Relief of benign or malignant obstruction*
    
  *Adjunct to stone therapy*
  For obstructionFor ESWLFor intraluminal lithotripsyFor ureteric instrumentationFor stone visualisation
    
  *Perioperative placement*
  Alignment of drainage elementsMaintenance of luminal calibreAfter ureteric interventionIdentification of ureter(s)
    
  *Management of urinary leakage*
  Leak from trauma or surgeryLeak due to ureteric fistula

###### 

Factors affecting complication rate and improved outcome in 220 patients, assessed by univariate analysis.

                                         Complications, *n* (%)   Improved outcome                    
  -------------------------------- ----- ------------------------ ------------------ ---------------- -------
  Side                                                                                                
   Right                           104   61 (58.7)                0.653              76 (73)          0.281
   Left                            116   71 (61.2)                                   81 (69.8)        
  Sex                                                                                                 
   Male                            133   67 (50.4)                \<0.001            103              0.009
   Female                          87    65 (74.7)                                   (77.4) 54 (62)   
  Pre-stenting urine culture                                                                          
   Unknown                         25    18 (72)                  0.198              17 (85)          0.016
   Negative                        168   97 (57.7)                                   128 (58.3)       
   Positive                        27    17 (63)                                     12 (57)          
  Urine culture during stenting                                                                       
   Unknown                         86    34 (39.5)                \<0.001            65 (90.3)        0.013
   Negative                        108   73 (67.6)                                   79 (80.6)        
   Positive                        26    25 (69.2)                                   13 (61.9)        
  Stent length (cm)                                                                                   
   22                              39    20 (51.3)                0.046              36 (92.3)        0.02
   24                              68    35 (51.5)                                   51 (75)          
   26                              106   77 (72.6)                                   92 (86.8)        
   28                              7     4                                           1                
  Stent diameter (F)                                                                                  
   4.7                             123   78 (63.4)                0.514              111 (90.2)       0.002
   6.0                             87    50 (57.5)                                   68 (78.2)        
   8.0                             10    8                                           2                
  Site of the upper coil                                                                              
   Pelvis                          182   117 (64.3)               0.387              157 (86.3)       0.095
   Calyx                           32    18 (56.3)                                   21 (65.6)        
   Ureter                          6     1                                           3                
  Site of the lower coil                                                                              
   Same side                       146   88 (60.3)                0.091              126 (80.8)       0.229
   Crossing midline                74    48 (64.9)                                   55 (74.3)        
  Lower coil shape                                                                                    
   Complete circle                 205   130 (63.4)               0.053              165 (80.5)       0.841
   Incomplete circle               15    6                                           15               
  Antibiotic prophylaxis                                                                              
   Yes                             180   110 (61)                 0.635              152 (84.4)       0.898
   No                              40    26 (65)                                     29 (72.5)        
  Number of stent changes                                                                             
   0                               210   128 (61)                 0.362              172 (81.9)       0.219
   1                               9     7                                           9                
   2                               1     1                                           0                
  Stent duration interval (days)                                                                      
   ⩽90                             155   84 (54)                  0.035              137 (88.4)       0.002
   \>90                            65    56 (86)                                     33 (50.8)        

###### 

Factors affecting patient's complications and effect on improved outcome in 220 patients assessed by multivariate analysis.

  Variable              Regression coefficient   SEM     Relative risk (95% CI)   *P*
  --------------------- ------------------------ ------- ------------------------ -------
  *Complication rate*                                                             
  Stent length (cm)     0.413                    0.172   1.511 (1.079--2.117)     0.016
                                                                                  
  *Outcome*                                                                       
  Age (years)           −0.149                   0.061   0.862 (0.765--0.971)     0.014
